SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences informs about press release

24 Apr 2023 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated April 24, 2023 titled ‘Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules, 0.5 g and 1 g’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1135.60 -14.90 (-1.30%)
13-Jul-2026 11:19 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1915.65
Dr. Reddys Labs. 1231.80
Cipla 1425.35
Zydus Lifesciences 1135.60
Lupin 2491.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: